Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development

Sun, Yixin; Zhao, Dongyang; Wang, Gang; Wang, Yan; Cao, Linlin; Sun, Jin; Jiang, Qikun; Zhang, He

doi:10.1016/j.apsb.2020.01.004

Cited by 165 publications

(96 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibitions of PRDX1 and MTH1 could introduce 8-oxo-dG at the 3′-ends of telomeric substrates, which could result in efficient inhibition of telomere extension by telomerase 46 . Additionally, photodynamic therapy (PDT) has been applied to achieve effective cancer treatment through the highly toxic ROS 53 , 54 , and accordingly MTH1 suppression was recently demonstrated to play a synergistic role for PDT on the basis of the improvement of cellular sensitivity to ROS in cancer cells 55 , 56 . These studies open new avenues for targeting oncogenic RAS and telomerase that are notoriously difficult anticancer targets by inhibiting MTH1, and also suggest that MTH1 inhibition might be suitable for polytherapy due to its synergistic effect.…”

Section: Discussionmentioning

confidence: 99%

Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives

Yin

Chen

2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Since accelerated metabolism produces much higher levels of reactive oxygen species (ROS) in cancer cells compared to ROS levels found in normal cells, human MutT homolog 1 (MTH1), which sanitizes oxidized nucleotide pools, was recently demonstrated to be crucial for the survival of cancer cells, but not required for the proliferation of normal cells. Therefore, dozens of MTH1 inhibitors have been developed with the aim of suppressing cancer growth by accumulating oxidative damage in cancer cells. While several inhibitors were indeed confirmed to be effective, some inhibitors failed to kill cancer cells, complicating MTH1 as a viable target for cancer eradication. In this review, we summarize the current status of developing MTH1 inhibitors as drug candidates, classify the MTH1 inhibitors based on their structures, and offer our perspectives toward the therapeutic potential against cancer through the targeting of MTH1.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives

Yin

Chen

2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…Moreover, although photodynamic therapy (PDT) has been widely investigated as a non-invasive therapeutic approach of cancers, the therapeutic effect of PDT is greatly impeded by tumor hypoxia (Sun et al 2020). MET has been found to improve tumor oxygenation, and cope with the hypoxic tumor environment (Song et al 2017).…”

Section: Nano-dds Of Met For Combination Cancer Therapymentioning

confidence: 99%

Emerging nanoparticulate drug delivery systems of metformin

Chen

Shan

Luo

et al. 2020

J. Pharm. Investig.

Self Cite

View full text Add to dashboard Cite

Background Driving the conventional drug in new applications has emerged as a research hotspot for disease treatment. Metformin (MET) is conventionally used for the treatment of type II diabetes. It has also been found to be a versatile molecule with wide biological functions, such as losing weight. anti-aging and anticancer activity. Rational design of nanoparticulate drug delivery systems (nano-DDS) could significantly improve drug delivery efficiency. Recently, a wide range of nano-DDS has been developed to improve the delivery efficacy of MET or to perform as versatile nanoplatforms for efficient drug delivery. Area covered In this review, we outline the emerging trends in advanced nano-DDS of MET, focusing on nano-DDS of MET for diabetes therapy, nano-DDS of MET for anticancer therapeutics, and nano-DDS of MET for other therapeutic aims. Expert opinion Despite the great progression in nano-DDS of MET, there's still a long way to truly put the conventional drug in new applications. Several important issues should be fully taken into consideration, such the manufacturing cost and economic burdens for patients, the biocompatibility and long-term toxicity of carrier materials, scale-up preparation difficulties, as well as the species gap between human beings and animal models.

show abstract

“…It causes cell death through generation of reactive oxygen species (ROS) such as hydroxyl radical (OH), singlet oxygen ( 1 O 2 ), and superoxide (O2 − ) intracellularly, upon photoexcitation of photosensitizers with light of suitable wavelength [ 64 ]. However, the low oxygen levels in the tumor microenvironment are also the main obstacle in PDT [ 87 ]. Therefore, PDT has been combined with PTT to enhance the oxygen levels and improve therapeutic efficacy [ 88 ].…”

Section: Pani-based Biomaterials For Tumor Ablationmentioning

confidence: 99%

Recent Advances of Polyaniline-Based Biomaterials for Phototherapeutic Treatments of Tumors and Bacterial Infections

et al. 2020

View full text Add to dashboard Cite

Conventional treatments fail to completely eradicate tumor or bacterial infections due to their inherent shortcomings. In recent years, photothermal therapy (PTT) has emerged as an attractive treatment modality that relies on the absorption of photothermal agents (PTAs) at a specific wavelength, thereby transforming the excitation light energy into heat. The advantages of PTT are its high efficacy, specificity, and minimal damage to normal tissues. To this end, various inorganic nanomaterials such as gold nanostructures, carbon nanostructures, and transition metal dichalcogenides have been extensively explored for PTT applications. Subsequently, the focus has shifted to the development of polymeric PTAs, owing to their unique properties such as biodegradability, biocompatibility, non-immunogenicity, and low toxicity when compared to inorganic PTAs. Among various organic PTAs, polyaniline (PANI) is one of the best-known and earliest-reported organic PTAs. Hence, in this review, we cover the recent advances and progress of PANI-based biomaterials for PTT application in tumors and bacterial infections. The future prospects in this exciting area are also addressed.

show abstract

Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development

Cited by 165 publications

References 114 publications

Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives

Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives

Emerging nanoparticulate drug delivery systems of metformin

Recent Advances of Polyaniline-Based Biomaterials for Phototherapeutic Treatments of Tumors and Bacterial Infections

Contact Info

Product

Resources

About